# Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

> **NCT01324544** · PHASE3 · WITHDRAWN · sponsor: **Purdue Pharma LP**

## Conditions studied

- Other Acute Postoperative Pain
- Prolonged Endotracheal Intubation

## Interventions

- **DRUG:** Buprenorphine IV

## Key facts

- **NCT ID:** NCT01324544
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-11
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to change in development plan.
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324544, "Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01324544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*